Jordyn Sava

A recent study highlights disparities in federal cancer funding, revealing that high-mortality cancers like lung and liver are significantly underfunded.

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a reevaluation of routine imaging practices.

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new therapies for rare cancers.

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical trials.

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential in targeted therapy advancements.

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative drug delivery.

CUE-101 combined with pembrolizumab shows promising results, achieving a 50% response rate in HPV-positive head and neck cancer patients.

The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

A recent trial reveals that targeted stereotactic radiation significantly reduces neurologic death rates in small cell lung cancer patients with brain metastases.

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA approval on the horizon.

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant therapy and brain metastases management.

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, enhancing standard chemotherapy outcomes.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

Hardeep Phull, MD, shared how telemedicine has transformed access, improved patient experience, and redefined care delivery for patients with cancer.

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

Enzalutamide and leuprolide significantly enhance survival in high-risk nonmetastatic prostate cancer, offering new hope for early intervention.

New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.

New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, paving the way for future studies.

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive efficacy and safety in clinical trials.

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision oncology care.

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.

A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile dysfunction rates, enhancing patient outcomes.

Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant therapy according to the MATTERHORN trial.